Literature DB >> 8288244

Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.

A Greco1, C Mariani, C Miranda, S Pagliardini, M A Pierotti.   

Abstract

TRK oncogenes are created by chromosomal rearrangements linking the tyrosine-kinase domain of the NTRK1 gene (encoding one of the receptors for the nerve growth factor) to foreign activating sequences. TRK oncogenes are frequently detected in human papillary thyroid carcinoma, as result of rearrangements involving at least three different activating genes. We have found that the rearrangements creating all the TRK oncogenes so far characterized fall within a 2.9-kb XbaI/SmaI restriction fragment of the NTRK1 gene. Here we report the nucleotide sequence and the exon organization of this fragment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8288244     DOI: 10.1006/geno.1993.1482

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  13 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

2.  AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.

Authors:  Radhika Iyer; Carly R Varela; Jane E Minturn; Ruth Ho; Anisha M Simpson; Jennifer E Light; Audrey E Evans; Huaqing Zhao; Kenneth Thress; Jeffrey L Brown; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2012-05-24       Impact factor: 3.333

3.  Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.

Authors:  Annalisa Pezzolo; Elena Rossi; Stefania Gimelli; Federica Parodi; Francesca Negri; Massimo Conte; Angela Pistorio; Angela Sementa; Vito Pistoia; Orsetta Zuffardi; Claudio Gambini
Journal:  Neuro Oncol       Date:  2008-10-15       Impact factor: 12.300

4.  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Authors:  Ha-Soon Choi; Paul V Rucker; Zhicheng Wang; Yi Fan; Pamela Albaugh; Greg Chopiuk; Francois Gessier; Fangxian Sun; Francisco Adrian; Guoxun Liu; Tami Hood; Nanxin Li; Yong Jia; Jianwei Che; Susan McCormack; Allen Li; Jie Li; Auzon Steffy; AnneMarie Culazzo; Celine Tompkins; Van Phung; Andreas Kreusch; Min Lu; Bin Hu; Apurva Chaudhary; Mahavir Prashad; Tove Tuntland; Bo Liu; Jennifer Harris; H Martin Seidel; Jon Loren; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2015-03-16       Impact factor: 4.345

Review 5.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

Review 6.  Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas.

Authors:  M A Pierotti; I Bongarzone; M G Borrello; C Mariani; C Miranda; G Sozzi; A Greco
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

7.  Suitability of animal models for studying radiation-induced thyroid cancer in humans: evidence from nuclear architecture.

Authors:  Manoj Gandhi; Yuri E Nikiforov
Journal:  Thyroid       Date:  2011-12       Impact factor: 6.568

8.  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Authors:  Pam Albaugh; Yi Fan; Yuan Mi; Fangxian Sun; Francisco Adrian; Nanxin Li; Yong Jia; Yelena Sarkisova; Andreas Kreusch; Tami Hood; Min Lu; Guoxun Liu; Shenlin Huang; Zuosheng Liu; Jon Loren; Tove Tuntland; Donald S Karanewsky; H Martin Seidel; Valentina Molteni
Journal:  ACS Med Chem Lett       Date:  2012-01-01       Impact factor: 4.345

Review 9.  Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.

Authors:  Alison M Schram; Matthew T Chang; Philip Jonsson; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2017-08-31       Impact factor: 66.675

10.  c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.

Authors:  Beata S Lipska; Elzbieta Drozynska; Paola Scaruffi; Gian Paolo Tonini; Ewa Izycka-Swieszewska; Szymon Zietkiewicz; Anna Balcerska; Danuta Perek; Alicja Chybicka; Wojciech Biernat; Janusz Limon
Journal:  BMC Cancer       Date:  2009-12-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.